A Study of LY3200882 in Participants With Solid Tumors (NCT02937272)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. The participant must have histological or cytological evidence of cancer.
2. Have adequate organ function.
3. Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1.
4. Are able to swallow capsules and tablets.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (18 Sites)

• University of Louisville — Louisville, Kentucky
• Weill Cornell Medical College — New York, New York
• University of Texas MD Anderson Cancer Center — Houston, Texas
• Calvary Mater Newcastle — Newcastle, New South Wales
• St Vincent's Hospital Sydney — Sydney, New South Wales
• Greenslopes Private Hospital — Greenslopes, Queensland
• Princess Margaret Hospital (Ontario) — Lai Chi Kok, Kowloon
• Hopital Saint-Louis — Paris, Cedex 10
• CHRU de Lille — Lille,
• Gustave Roussy — Villejuif,
• Universitätsklinikum Würzburg A. ö. R. — Würzburg, Bavaria
• Charité Campus Virchow-Klinikum — Berlin,
• Istituto Clinico Humanitas — Rozzano, Milano
• Ospedale Policlinico Giambattista Rossi, Borgo Roma — Verona,
• National Cancer Center Hospital — Chuo-Ku, Tokyo
• Hospital Universitari Vall d'Hebron — Barcelona,
• Hospital Universitario 12 de Octubre — Madrid,
• Hospital Clínico Universitario de Valencia — Valencia,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.